Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
16 hedge funds and large institutions have $7.67M invested in Virpax Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
45% more funds holding
Funds holding: 11 → 16 (+5)
33% less capital invested
Capital invested by funds: $11.4M → $7.67M (-$3.78M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$404K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$199K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$156K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$104K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$62.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$1.3M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$479K |
| 3 |
Two Sigma Investments
New York
|
-$123K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$90K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$7.21K |
VRPX Hedge Fund Activity: Q4 2021 in Review
16 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q4 2021, worth a combined $7.67M — down 33% from $11.4M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VRPX positions and 4 closed out — a net gain of 5 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $404K. The largest seller was Altium Capital Management, exiting entirely with an estimated $1.3M sold.
- 16 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q4 2021, up from 11 in Q3 2021.
- Funds reported $7.67M of Virpax Pharmaceuticals, Inc. Common Stock stock for Q4 2021, down 33% quarter-over-quarter.
- 9 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 4 closed out, a net change of +5 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Citadel Advisors, an estimated $404K added.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q4 2021 was Altium Capital Management, an estimated $1.3M sold.
Based on aggregated 13F filings for Q4 2021.